Pfizer will share a portion of any higher overseas drug revenue with the U. Health and Human Services Department under a reported “most favored nation” contract.
A media report states that the U.S. Department of Health and Human Services (HHS) will receive a share of any increased revenue Pfizer generates by charging higher drug prices abroad. The arrangement is described as a “most favored nation” contract.
The report provides limited detail beyond the basic premise of revenue sharing and does not disclose the contract’s terms, duration, or the specific percentage of revenue to be allocated to HHS.
Further information about the contract’s implementation, regulatory approval, or impact on drug pricing has not been disclosed, leaving the full scope of the agreement uncertain.